Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

Por Wingren, S., Stål, O., Nordenskjöld, B.
Publicado em 1994

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

Por Pérez-Tenorio, G, Stål, O
Publicado em 2002

AKT-1 and BCL-2 co-expression in breast cancer patients correlates with better survival

Por Pérez-Tenorio, G, Stål, O
Publicado em 2000

17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer

Por Gunnarsson, C, Hellqvist, E, Stål, O
Publicado em 2005

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

Por Stål, O., Carstensen, J., Hatschek, T., Nordenskjöld, B.
Publicado em 1992

p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.

Por Stenmark-Askmalm, M., Stål, O., Olsen, K., Nordenskjöld, B.
Publicado em 1995

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer

Por Stal, O, Akerberg, L, Nordenskjold, B, Olsson, B, Rutqvist, LE, Skoog, L
Publicado em 2000

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Por Weiner, M., Skoog, L., Fornander, T., Nordenskjöld, B., Sgroi, D. C., Stål, O.
Publicado em 2013

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

Por Stål, O., Skoog, L., Rutqvist, L. E., Carstensen, J. M., Wingren, S., Sullivan, S., Andersson, A. C., Dufmats, M., Nordenskjöld, B.
Publicado em 1994

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Por Jirström, K, Rydén, L, Anagnostaki, L, Nordenskjöld, B, Stål, O, Thorstenson, S, Chebil, G, Jönsson, P-E, Fernö, M, Landberg, G
Publicado em 2005

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

Por Rosell, J, Nordenskjöld, B, Bengtsson, N-O, Fornander, T, Hatschek, T, Lindman, H, Malmström, P-O, Wallgren, A, Stål, O, Carstensen, J
Publicado em 2011

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

Por Borg, A., Lennerstrand, J., Stenmark-Askmalm, M., Fernö, M., Brisfors, A., Ohrvik, A., Stål, O., Killander, D., Lane, D., Brundell, J.
Publicado em 1995

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

Por Jerevall, P-L, Ma, X-J, Li, H, Salunga, R, Kesty, N C, Erlander, M G, Sgroi, D C, Holmlund, B, Skoog, L, Fornander, T, Nordenskjöld, B, Stål, O
Publicado em 2011

Physics at the [Formula: see text] linear collider

Por Moortgat-Pick, G., Baer, H., Battaglia, M., Belanger, G., Fujii, K., Kalinowski, J., Heinemeyer, S., Kiyo, Y., Olive, K., Simon, F., Uwer, P., Wackeroth, D., Zerwas, P. M., Arbey, A., Asano, M., Bagger, J., Bechtle, P., Bharucha, A., Brau, J., Brümmer, F., Choi, S. Y., Denner, A., Desch, K., Dittmaier, S., Ellwanger, U., Englert, C., Freitas, A., Ginzburg, I., Godfrey, S., Greiner, N., Grojean, C., Grünewald, M., Heisig, J., Höcker, A., Kanemura, S., Kawagoe, K., Kogler, R., Krawczyk, M., Kronfeld, A. S., Kroseberg, J., Liebler, S., List, J., Mahmoudi, F., Mambrini, Y., Matsumoto, S., Mnich, J., Mönig, K., Mühlleitner, M. M., Pöschl, R., Porod, W., Porto, S., Rolbiecki, K., Schmitt, M., Serpico, P., Stanitzki, M., Stål, O., Stefaniak, T., Stöckinger, D., Weiglein, G., Wilson, G. W., Zeune, L., Moortgat, F., Xella, S., Bagger, J., Brau, J., Ellis, J., Kawagoe, K., Komamiya, S., Kronfeld, A. S., Mnich, J., Peskin, M., Schlatter, D., Wagner, A., Yamamoto, H.
Publicado no Eur Phys J C Part Fields (2015)